Key Features Relevant to Select Antigens and TCR From the MHC-Mismatched Repertoire to Treat Cancer

Adoptive transfer of T cells transgenic for tumor-reactive T-cell receptors (TCR) is an attractive immunotherapeutic approach. However, clinical translation is so far limited due to challenges in the identification of suitable target antigens as well as TCRs that are concurrent safe and efficient. Definition of key characteristics relevant for effective and specific tumor rejection is essential to improve current TCR-based adoptive T-cell immunotherapies. We here characterized in-depth two TCRs derived from the human leukocyte antigen (HLA)-mismatched allogeneic repertoire targeting two different myeloperoxidase (MPO)-derived peptides presented by the same HLA-restriction element side by side comprising state of the art biochemical and cellular in vitro, in vivo, and in silico experiments. In vitro experiments reveal comparable functional avidities, off-rates, and cytotoxic activities for both TCRs. However, we observed differences especially with respect to cytokine secretion and cross-reactivity as well as in vivo activity. Biochemical and in silico analyses demonstrate different binding qualities of MPO-peptides to the HLA-complex determining TCR qualities. We conclude from our biochemical and in silico analyses of peptide-HLA-binding that rigid and high-affinity binding of peptides is one of the most important factors for isolation of TCRs with high specificity and tumor rejection capacity from the MHC-mismatched repertoire. Based on our results, we developed a workflow for selection of such TCRs with high potency and safety profile suitable for clinical translation.

[1]  M. Quadroni,et al.  Fine-Tuning of Optimal TCR Signaling in Tumor-Redirected CD8 T Cells by Distinct TCR Affinity-Mediated Mechanisms , 2017, Front. Immunol..

[2]  L. Naldini,et al.  NY-ESO-1 TCR single edited stem and central memory T cells to treat multiple myeloma without graft-versus-host disease. , 2017, Blood.

[3]  T. Blankenstein,et al.  T-cell Receptors for Clinical Therapy: In Vitro Assessment of Toxicity Risk , 2017, Clinical Cancer Research.

[4]  R. Weichselbaum,et al.  Tumour ischaemia by interferon-γ resembles physiological blood vessel regression , 2017, Nature.

[5]  R. Hagedoorn,et al.  TCR-based therapy for multiple myeloma and other B-cell malignancies targeting intracellular transcription factor BOB1. , 2017, Blood.

[6]  M. Mann,et al.  Direct identification of clinically relevant neoepitopes presented on native human melanoma tissue by mass spectrometry , 2016, Nature Communications.

[7]  Christian Stemberger,et al.  Flow cytometry‐based TCR‐ligand Koff‐rate assay for fast avidity screening of even very small antigen‐specific T cell populations ex vivo , 2016, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

[8]  M. Aichler,et al.  Immuno-PET Imaging of Engineered Human T Cells in Tumors. , 2016, Cancer research.

[9]  Morten Nielsen,et al.  Gapped sequence alignment using artificial neural networks: application to the MHC class I system , 2016, Bioinform..

[10]  C. Simmerling,et al.  ff14SB: Improving the Accuracy of Protein Side Chain and Backbone Parameters from ff99SB. , 2015, Journal of chemical theory and computation.

[11]  J. E. Brewer,et al.  NY-ESO-1 specific TCR engineered T-cells mediate sustained antigen-specific antitumor effects in myeloma , 2015, Nature Medicine.

[12]  S. Buus,et al.  A molecular switch in immunodominant HIV-1-specific CD8 T-cell epitopes shapes differential HLA-restricted escape , 2015, Retrovirology.

[13]  J. Slotta-Huspenina,et al.  Therapeutic targeting of naturally presented myeloperoxidase-derived HLA peptide ligands on myeloid leukemia cells by TCR-transgenic T cells , 2014, Leukemia.

[14]  M. Nielsen,et al.  NetMHCstab – predicting stability of peptide–MHC‐I complexes; impacts for cytotoxic T lymphocyte epitope discovery , 2014, Immunology.

[15]  Duncan Poole,et al.  Routine Microsecond Molecular Dynamics Simulations with AMBER on GPUs. 2. Explicit Solvent Particle Mesh Ewald. , 2013, Journal of chemical theory and computation.

[16]  Bent K Jakobsen,et al.  Identification of a Titin-Derived HLA-A1–Presented Peptide as a Cross-Reactive Target for Engineered MAGE A3–Directed T Cells , 2013, Science Translational Medicine.

[17]  M. Neuenhahn,et al.  TCR-Ligand koff Rate Correlates with the Protective Capacity of Antigen-Specific CD8+ T Cells for Adoptive Transfer , 2013, Science Translational Medicine.

[18]  Daniel R Roe,et al.  PTRAJ and CPPTRAJ: Software for Processing and Analysis of Molecular Dynamics Trajectory Data. , 2013, Journal of chemical theory and computation.

[19]  John Sidney,et al.  Relapse or eradication of cancer is predicted by peptide-major histocompatibility complex affinity. , 2013, Cancer cell.

[20]  S. Rosenberg,et al.  T-cell receptor affinity and avidity defines antitumor response and autoimmunity in T-cell immunotherapy , 2013, Proceedings of the National Academy of Sciences.

[21]  L. Zender,et al.  T-helper-1-cell cytokines drive cancer into senescence , 2013, Nature.

[22]  Tongguang Wang,et al.  Cancer Regression and Neurological Toxicity Following Anti-MAGE-A3 TCR Gene Therapy , 2013, Journal of immunotherapy.

[23]  Holger Gohlke,et al.  MMPBSA.py: An Efficient Program for End-State Free Energy Calculations. , 2012, Journal of chemical theory and computation.

[24]  Hiroaki Tanaka,et al.  Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival , 2012, Nature Medicine.

[25]  G. Altan-Bonnet,et al.  Distinct influences of peptide-MHC quality and quantity on in vivo T-cell responses , 2012, Proceedings of the National Academy of Sciences.

[26]  A. Bagg,et al.  Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. , 2011, The New England journal of medicine.

[27]  M. Raffeld,et al.  Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  D. Busch,et al.  A Single TCRα-Chain with Dominant Peptide Recognition in the Allorestricted HER2/neu-Specific T Cell Repertoire , 2009, The Journal of Immunology.

[29]  Thomas Lengauer,et al.  Docking and scoring with alternative side‐chain conformations , 2009, Proteins.

[30]  Morten Nielsen,et al.  Accurate approximation method for prediction of class I MHC affinities for peptides of length 8, 10 and 11 using prediction tools trained on 9mers , 2008, Bioinform..

[31]  T. Schumacher,et al.  Conditional MHC class I ligands and peptide exchange technology for the human MHC gene products HLA-A1, -A3, -A11, and -B7 , 2008, Proceedings of the National Academy of Sciences.

[32]  D. Busch,et al.  Allorestricted T cells with specificity for the FMNL1-derived peptide PP2 have potent antitumor activity against hematologic and other malignancies. , 2007, Blood.

[33]  Thomas Lengauer,et al.  IRECS: A new algorithm for the selection of most probable ensembles of side‐chain conformations in protein models , 2007, Protein science : a publication of the Protein Society.

[34]  K. Garcia,et al.  How a Single T Cell Receptor Recognizes Both Self and Foreign MHC , 2007, Cell.

[35]  Ralf-Holger Voss,et al.  Facilitating matched pairing and expression of TCR chains introduced into human T cells. , 2007, Blood.

[36]  Joo Chuan Tong,et al.  A practical guide to structure-based prediction of MHC-binding peptides. , 2007, Methods in molecular biology.

[37]  Shamsul A. Khan,et al.  Targeting the activation-induced antigen CD137 can selectively deplete alloreactive T cells from antileukemic and antitumor donor T-cell lines. , 2007, Blood.

[38]  R. Hagedoorn,et al.  Efficiency of T-cell receptor expression in dual-specific T cells is controlled by the intrinsic qualities of the TCR chains within the TCR-CD3 complex. , 2007, Blood.

[39]  M. Heemskerk,et al.  Designer T cells by T cell receptor replacement , 2006, European journal of immunology.

[40]  T. Schumacher,et al.  Generation of peptide–MHC class I complexes through UV-mediated ligand exchange , 2006, Nature Protocols.

[41]  Thomas Lengauer,et al.  DynaPred: A structure and sequence based method for the prediction of MHC class I binding peptide sequences and conformations , 2006, ISMB.

[42]  Amos Bairoch,et al.  ScanProsite: detection of PROSITE signature matches and ProRule-associated functional and structural residues in proteins , 2006, Nucleic Acids Res..

[43]  C. Meijer,et al.  Codon modification of T cell receptors allows enhanced functional expression in transgenic human T cells. , 2006, Clinical immunology.

[44]  B. Engels,et al.  Articles on similar topics can be found in the following Blood collections Gene Therapy (517 articles) , 2005 .

[45]  Nathan A. Baker,et al.  PDB2PQR: an automated pipeline for the setup of Poisson-Boltzmann electrostatics calculations , 2004, Nucleic Acids Res..

[46]  D. Case,et al.  Exploring protein native states and large‐scale conformational changes with a modified generalized born model , 2004, Proteins.

[47]  Hans-Georg Rammensee,et al.  MHC ligands and peptide motifs: first listing , 2004, Immunogenetics.

[48]  O. Lund,et al.  novel sequence representations Reliable prediction of T-cell epitopes using neural networks with , 2003 .

[49]  D. Busch,et al.  Reversible MHC multimer staining for functional isolation of T-cell populations and effective adoptive transfer , 2002, Nature Medicine.

[50]  Nathan A. Baker,et al.  Electrostatics of nanosystems: Application to microtubules and the ribosome , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[51]  Alexis M. Kalergis,et al.  Efficient T cell activation requires an optimal dwell-time of interaction between the TCR and the pMHC complex , 2001, Nature Immunology.

[52]  P. Kollman,et al.  Calculating structures and free energies of complex molecules: combining molecular mechanics and continuum models. , 2000, Accounts of chemical research.

[53]  H. Rammensee,et al.  SYFPEITHI: database for MHC ligands and peptide motifs , 1999, Immunogenetics.

[54]  S. Rosenberg,et al.  High avidity CTLs for two self-antigens demonstrate superior in vitro and in vivo antitumor efficacy. , 1999, Journal of immunology.

[55]  P. Kollman,et al.  Continuum Solvent Studies of the Stability of DNA, RNA, and Phosphoramidate−DNA Helices , 1998 .

[56]  D. Stuart,et al.  Antagonist HIV-1 Gag Peptides Induce Structural Changes in HLA B8 , 1996, The Journal of experimental medicine.

[57]  X. Jin,et al.  The human cytotoxic T-lymphocyte (CTL) response to cytomegalovirus is dominated by structural protein pp65: frequency, specificity, and T-cell receptor usage of pp65-specific CTL , 1996, Journal of virology.

[58]  J. Berzofsky,et al.  Selective expansion of high- or low-avidity cytotoxic T lymphocytes and efficacy for adoptive immunotherapy. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[59]  A. Lanzavecchia,et al.  Different responses are elicited in cytotoxic T lymphocytes by different levels of T cell receptor occupancy , 1996, The Journal of experimental medicine.

[60]  K Schulten,et al.  VMD: visual molecular dynamics. , 1996, Journal of molecular graphics.

[61]  D. Margulies,et al.  Determinant selection of major histocompatibility complex class I- restricted antigenic peptides is explained by class I-peptide affinity and is strongly influenced by nondominant anchor residues , 1994, The Journal of experimental medicine.

[62]  K. Parker,et al.  Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. , 1994, Journal of immunology.

[63]  R. Zinkernagel,et al.  Discrepancy between in vitro measurable and in vivo virus neutralizing cytotoxic T cell reactivities. Low T cell receptor specificity and avidity sufficient for in vitro proliferation or cytotoxicity to peptide-coated target cells but not for in vivo protection. , 1992, Journal of immunology.

[64]  Peter J. Rousseeuw,et al.  Finding Groups in Data: An Introduction to Cluster Analysis , 1990 .

[65]  W. C. Still,et al.  Semianalytical treatment of solvation for molecular mechanics and dynamics , 1990 .

[66]  H. Berendsen,et al.  Molecular dynamics with coupling to an external bath , 1984 .

[67]  W. L. Jorgensen,et al.  Comparison of simple potential functions for simulating liquid water , 1983 .

[68]  G. Ciccotti,et al.  Numerical Integration of the Cartesian Equations of Motion of a System with Constraints: Molecular Dynamics of n-Alkanes , 1977 .